- Home
- ARR vs NRIX Comparison
ARR vs NRIX Comparison
Compare ARR & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARR
- NRIX
- Stock Information
- Founded
- ARR 2008
- NRIX 2009
- Country
- ARR United States
- NRIX United States
- Employees
- ARR N/A
- NRIX N/A
- Industry
- ARR Real Estate Investment Trusts
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- ARR Real Estate
- NRIX Health Care
- Exchange
- ARR Nasdaq
- NRIX Nasdaq
- Market Cap
- ARR 1.3B
- NRIX 1.1B
- IPO Year
- ARR N/A
- NRIX 2020
- Fundamental
- Price
- ARR $16.96
- NRIX $10.18
- Analyst Decision
- ARR Hold
- NRIX Strong Buy
- Analyst Count
- ARR 5
- NRIX 17
- Target Price
- ARR $21.00
- NRIX $30.71
- AVG Volume (30 Days)
- ARR 2.7M
- NRIX 950.5K
- Earning Date
- ARR 04-23-2025
- NRIX 04-08-2025
- Dividend Yield
- ARR 16.98%
- NRIX N/A
- EPS Growth
- ARR N/A
- NRIX N/A
- EPS
- ARR N/A
- NRIX N/A
- Revenue
- ARR $44,778,000.00
- NRIX $56,417,000.00
- Revenue This Year
- ARR $532.77
- NRIX $15.73
- Revenue Next Year
- ARR $15.62
- NRIX N/A
- P/E Ratio
- ARR N/A
- NRIX N/A
- Revenue Growth
- ARR 41.14
- NRIX N/A
- 52 Week Low
- ARR $13.18
- NRIX $8.18
- 52 Week High
- ARR $21.93
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- ARR 61.28
- NRIX 43.38
- Support Level
- ARR $15.88
- NRIX $9.02
- Resistance Level
- ARR $16.64
- NRIX $11.56
- Average True Range (ATR)
- ARR 0.42
- NRIX 0.59
- MACD
- ARR 0.24
- NRIX -0.03
- Stochastic Oscillator
- ARR 89.60
- NRIX 34.52
About ARR ARMOUR Residential REIT Inc.
ARMOUR Residential REIT Inc operate in the U.S. and invest in fixed rate residential, adjustable rate and hybrid adjustable rate residential MBS issued or guaranteed by U.S. GSEs or guaranteed by Ginnie Mae. It also invest in U.S. Treasury Securities and money market instruments.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.